NIH R01 · 2025
Advancement of a poxvirus antiviral
Project Summary/Abstract Poxviruses are a large group of human pathogens that include variola (the causative agent of smallpox), mpox, and cowpox. Recent global outbreaks of increasingly virulent mpox clades have underscored the growing need for both prophylactic vaccination and small molecule therapeutics to control the spread and severity of poxviral disease. To date, only two antiviral drug classes (tecovirimat and cidofovir/brincidofovir) have been FDA-approved for treating smallpox; both were developed and approved for poxviruses according to the Animal Rule with no efficacy testing in humans. The WHO, CDC and other agencies have stated a strong desire for at least two safe, effective…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.